Search

Displaying results 4221 - 4230 of 5897 in total
  1. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]

  3. Drug

    Talactoferrin alfa

    go.drugbank.com/drugs/DB05426
    Investigational

    It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

  4. Drug

    N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide

    go.drugbank.com/drugs/DB03456
    Experimental

    It is known to target cathepsin K. … This compound belongs to the n-acyl-alpha amino acids and derivatives.

  5. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]

  6. Drug

    3-(5-Amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid

    go.drugbank.com/drugs/DB08668
    Experimental

    This compound belongs to the aminobenzoic acid derivatives. … These are benzoic acids (or derivatives thereof) containing an amine group attached to the benzene moiety. 3-(5-amino-3-imino-3H-pyrazol-4-ylazo)-benzoic acid targets the protein methionine aminopeptidase

  7. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  8. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.

  9. Drug

    Rose bengal

    go.drugbank.com/drugs/DB11182
    ApprovedInvestigational

    Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells.

  10. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation